Federal Register / Vol. 85, No. 234 / Friday, December 4, 2020 / Notices 78363 

agreements, written or oral, express or 

implied between the parties concerning 

the subject matter of the investigation.’’ 

19 CFR 210.21(b)(1). 

Consistent with Commission Rule 

210.21(b)(1), redacted versions of a 

patent license agreement and a 

settlement agreement between Rovi and 

Comcast were attached to the motion as 

Exhibits 1 and 2 and the unredacted 

agreements were filed separately under 

a confidential header. The moving 

parties submit that the agreements 

resolve the allegations of infringement 

against Comcast in the investigation. 

Motion at 1. In further compliance with 

Commission Rule 210.21(b)(1), the 

motion contains a statement that there 

are no other agreements, written or oral, 

express or implied between the parties 

concerning the subject matter of the 

investigation. Id. at 2. The movants 

submit that termination is in the interest 

of the public and administrative 

economy. Id. at 3. 

Pursuant to Commission Rule 

210.50(b)(2), the Commission finds no 

evidence that terminating this 

investigation will adversely affect the 

public health and welfare, competitive 

conditions in the U.S. economy, the 

production of like or directly 

competitive articles in the United 

States, or U.S. customers. 19 CFR 

210.50(b)(2). Moreover, the public 

interest generally favors settlement to 

avoid needless litigation and to 

conserve public resources. See, e.g., 

Certain Semiconductor Devices, 

Products Containing the Same, and 

Components Thereof (II), Inv. No. 337– 

TA–1177, Order No. 5 at 2 (Nov. 25, 

2019), unreviewed by Comm’n Notice 

(Dec. 20, 2019). 

Accordingly, the Commission finds 

that the joint motion for termination 

satisfies Commission Rules 210.21(a)(2) 

and (b)(1) (19 CFR 210.21(a)(2), (b)(1)) 

and that termination of the investigation 

is not contrary to the public interest. 

Accordingly, the Commission grants 

the joint motion to terminate the 

investigation in its entirety based on 

settlement. The investigation is 

terminated. 

The Commission vote for this 

determination took place on November 

30, 2020. 

The authority for the Commission’s 

determination is contained in section 

337 of the Tariff Act of 1930, as 

amended, 19 U.S.C. 1337, and in part 

210 of the Commission’s Rules of 

Practice and Procedure, 19 CFR part 

210. 

By order of the Commission. 

Issued: November 30, 2020. 

Katherine Hiner, 

Supervisory Attorney. 

[FR Doc. 2020–26685 Filed 12–3–20; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–751] 

Importer of Controlled Substances 

Application: Janssen Pharmaceuticals 

Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Janssen Pharmaceuticals Inc. 

has applied to be registered as an 

importer of basic class(es) of controlled 

substance(s). Refer to Supplemental 

Information listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before January 4, 2021. Such persons 

may also file a written request for a 

hearing on the application on or before 

January 4, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing must 

be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for a 

hearing should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on November 11, 2020, 

Janssen Pharmaceuticals Inc., 1440 

Olympic Drive, Athens, Georgia 30601– 

1645, applied to be registered as an 

importer of the following basic class(es) 

of controlled substance(s): 

Controlled substance Drug code Schedule 

Thebaine .................................................................................................................................................................. 9333 II 

Poppy Straw Concentrate ........................................................................................................................................ 9670 II 

Tapentadol ............................................................................................................................................................... 9780 II 

The company plans to import 

intermediate forms of Tapentadol (9780) 

and Thebaine (9333) for further 

manufacturing prior to distribution to 

its customers. The company plans to 

import Poppy Straw Concentrate (9670) 

to bulk manufacture other controlled 

substances. No other activity for these 

drug codes is authorized for this 

registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2020–26653 Filed 12–3–20; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Notice of Lodging of Proposed 

Consent Decree Under the 

Comprehensive Environmental 

Response, Compensation and Liability 

Act 

On November 27, 2020, the 

Department of Justice lodged a proposed 

Consent Decree with the United States 

District Court for the District of New 

Jersey in the lawsuit entitled United 

States et al. v. Unimatic Manufacturing, 

Corp. et al., Civil Action No. 2:20-cv17284. 

The proposed Consent Decree would 

resolve claims the United States, New 

Jersey Department of Environmental 

Protection (‘‘NJDEP’’) and the 

Administrator of the New Jersey Spill 

Compensation Fund have brought 

pursuant to Section 107 of the 

Comprehensive Environmental 

Response, Compensation, and Liability